| Medical Condition | Long QT Syndrome Type 2 |
|---|---|
| Facility/Clinic | 1202 Medical Center Dr |
| Description | Wave II is sponsored by Thryv Therapeutics Inc., a company dedicated to advancing new treatment options for inherited cardiac rhythm conditions. The study is evaluating an investigational medication called THRV-1268, an oral medication taken twice daily for Long QT Syndrome. This study will help understand whether THRV-1268 may support healthier, more stable heart rhythms in people with LQTS2. We are looking for people who: -Are 18 years of age or older -Have LQTS 2 genotype with demonstration of KCNH2 mutation -Have a QTcF interval >480 ms and ≤600 ms Additional criteria apply, which the study team will be happy to discuss with you. Call 910-362-4040 or email byoppchester@wilmingtonhealth.com for more information. |
The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-362-4040 between the hours of 8am-5pm for general research questions.